lenvima

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

ruth 12 9 月

6 minutes

TOKYO and RAHWAY, N.J., Sep 12 […]

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial

ruth 4 8 月

4 minutes

TOKYO and RAHWAY, N.J., Aug 4, […]

Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

ruth 25 2 月

3 minutes

TOKYO and KENILWORTH, N.J., Fe […]

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma

ruth 20 1 月

3 minutes

TOKYO, Jan 20, 2022 – (J […]

European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma

ruth 29 11 月

3 minutes

TOKYO and KENILWORTH, N.J., No […]

FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)

ruth 12 8 月

18 minutes

TOKYO and KENILWORTH, N.J., Au […]

Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib

ruth 8 6 月

5 minutes

TOKYO and KENILWORTH, N.J., Ju […]

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

ruth 23 3 月

2 minutes

TOKYO, Mar 23, 2021 – (J […]

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

ruth 15 2 月

4 minutes

TOKYO, Feb 15, 2021 – (J […]

Copyright © 2020 ASEANPR.Com All rights reserved.